233 related articles for article (PubMed ID: 2491940)
1. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo.
Goodman WK; Price LH; Rasmussen SA; Delgado PL; Heninger GR; Charney DS
Arch Gen Psychiatry; 1989 Jan; 46(1):36-44. PubMed ID: 2491940
[TBL] [Abstract][Full Text] [Related]
2. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory.
Jenike MA; Hyman S; Baer L; Holland A; Minichiello WE; Buttolph L; Summergrad P; Seymour R; Ricciardi J
Am J Psychiatry; 1990 Sep; 147(9):1209-15. PubMed ID: 2143637
[TBL] [Abstract][Full Text] [Related]
3. Fluvoxamine treatment of obsessive-compulsive disorder.
Perse TL; Greist JH; Jefferson JW; Rosenfeld R; Dar R
Am J Psychiatry; 1987 Dec; 144(12):1543-8. PubMed ID: 3120604
[TBL] [Abstract][Full Text] [Related]
4. Treatment of severe obsessive-compulsive disorder with fluvoxamine.
Price LH; Goodman WK; Charney DS; Rasmussen SA; Heninger GR
Am J Psychiatry; 1987 Aug; 144(8):1059-61. PubMed ID: 3111279
[TBL] [Abstract][Full Text] [Related]
5. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.
Goodman WK; Price LH; Delgado PL; Palumbo J; Krystal JH; Nagy LM; Rasmussen SA; Heninger GR; Charney DS
Arch Gen Psychiatry; 1990 Jun; 47(6):577-85. PubMed ID: 2112374
[TBL] [Abstract][Full Text] [Related]
6. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy.
McDougle CJ; Price LH; Goodman WK; Charney DS; Heninger GR
J Clin Psychopharmacol; 1991 Jun; 11(3):175-84. PubMed ID: 1820757
[TBL] [Abstract][Full Text] [Related]
7. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.
McDougle CJ; Goodman WK; Leckman JF; Lee NC; Heninger GR; Price LH
Arch Gen Psychiatry; 1994 Apr; 51(4):302-8. PubMed ID: 8161290
[TBL] [Abstract][Full Text] [Related]
8. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
[TBL] [Abstract][Full Text] [Related]
9. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.
Hollander E; Koran LM; Goodman WK; Greist JH; Ninan PT; Yang H; Li D; Barbato LM
J Clin Psychiatry; 2003 Jun; 64(6):640-7. PubMed ID: 12823077
[TBL] [Abstract][Full Text] [Related]
10. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder.
McDougle CJ; Goodman WK; Leckman JF; Holzer JC; Barr LC; McCance-Katz E; Heninger GR; Price LH
Am J Psychiatry; 1993 Apr; 150(4):647-9. PubMed ID: 8465885
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder.
McDougle CJ; Goodman WK; Leckman JF; Barr LC; Heninger GR; Price LH
J Clin Psychopharmacol; 1993 Oct; 13(5):354-8. PubMed ID: 8227493
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.
Piccinelli M; Pini S; Bellantuono C; Wilkinson G
Br J Psychiatry; 1995 Apr; 166(4):424-43. PubMed ID: 7795913
[TBL] [Abstract][Full Text] [Related]
13. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
Zheng H; Jia F; Han H; Wang S; Guo G; Quan D; Li G; Huang H
Eur Neuropsychopharmacol; 2019 Mar; 29(3):397-404. PubMed ID: 30595354
[TBL] [Abstract][Full Text] [Related]
14. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison.
Koran LM; McElroy SL; Davidson JR; Rasmussen SA; Hollander E; Jenike MA
J Clin Psychopharmacol; 1996 Apr; 16(2):121-9. PubMed ID: 8690827
[TBL] [Abstract][Full Text] [Related]
15. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study.
Mundo E; Guglielmo E; Bellodi L
Int Clin Psychopharmacol; 1998 Sep; 13(5):219-24. PubMed ID: 9817627
[TBL] [Abstract][Full Text] [Related]
16. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder.
Milanfranchi A; Ravagli S; Lensi P; Marazziti D; Cassano GB
Int Clin Psychopharmacol; 1997 May; 12(3):131-6. PubMed ID: 9248868
[TBL] [Abstract][Full Text] [Related]
17. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.
Bogetto F; Bellino S; Vaschetto P; Ziero S
Psychiatry Res; 2000 Oct; 96(2):91-8. PubMed ID: 11063782
[TBL] [Abstract][Full Text] [Related]
18. Neurological soft signs as predictors of treatment response to selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
Hollander E; Kaplan A; Schmeidler J; Yang H; Li D; Koran LM; Barbato LM
J Neuropsychiatry Clin Neurosci; 2005; 17(4):472-7. PubMed ID: 16387985
[TBL] [Abstract][Full Text] [Related]
19. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
[TBL] [Abstract][Full Text] [Related]
20. Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial.
Shalbafan M; Malekpour F; Tadayon Najafabadi B; Ghamari K; Dastgheib SA; Mowla A; Shirazi E; Eftekhar Ardebili M; Ghazizadeh-Hashemi M; Akhondzadeh S
J Psychopharmacol; 2019 Nov; 33(11):1407-1414. PubMed ID: 31575326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]